Lou Feiran, Sima Camelia S, Rusch Valerie W, Jones David R, Huang James
Department of Surgery, SUNY Downstate Medical Center, Brooklyn, New York.
Department of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Ann Thorac Surg. 2014 Nov;98(5):1755-60; discussion 1760-1. doi: 10.1016/j.athoracsur.2014.05.070. Epub 2014 Aug 7.
The benefits of screening for non-small cell lung cancer (NSCLC) have been established for high-risk individuals, and recent guidelines advocate continued surveillance after curative therapy. Yet the optimal posttreatment surveillance strategy remains to be determined. We compared patterns of recurrence and modes of detection in surgically treated patients with pathologic early-stage and locally advanced NSCLC.
Consecutive patients who had undergone resection for stage I-IIIA NSCLC from 2004 to 2009 were identified from a prospectively maintained institutional database. All patients received interval chest computed tomography (CT) scans every 6 to 12 months after treatment.
In total, 1,640 patients were identified: 181 of 346 patients with stage IIIA NSCLC (52%) and 257 of 1,294 patients with stage I-II NSCLC (20%) experienced recurrences. Surveillance CT detected asymptomatic recurrences in 157 stage I-II patients (61%) and 89 stage IIIA patients (49%) (p=0.045). Symptoms led to detection of recurrences more often in stage IIIA patients (73, 40%) than in stage I-II patients (81, 32%). Distant recurrences were more common in stage IIIA patients than in stage I-II patients (153, 85%, vs 190, 74%; p=0.01). In stage IIIA patients, the risk of recurrence was highest during the first 2 years after operation, but it remained substantial into year 4.
Stage IIIA patients had fewer recurrences detected by surveillance CT, a higher rate of symptomatic presentation, a markedly higher risk of recurrence, and a higher propensity for distant recurrence. Surveillance strategies may need to account for stage-specific differences.
非小细胞肺癌(NSCLC)筛查对高危个体的益处已得到证实,近期指南提倡在根治性治疗后继续进行监测。然而,最佳的治疗后监测策略仍有待确定。我们比较了接受手术治疗的病理早期和局部晚期NSCLC患者的复发模式和检测方式。
从一个前瞻性维护的机构数据库中识别出2004年至2009年接受I-IIIA期NSCLC切除术的连续患者。所有患者在治疗后每6至12个月接受一次胸部计算机断层扫描(CT)检查。
总共识别出1640例患者:346例IIIA期NSCLC患者中有181例(52%)复发,1294例I-II期NSCLC患者中有257例(20%)复发。监测CT在157例I-II期患者(61%)和89例IIIA期患者(49%)中检测到无症状复发(p=0.045)。症状导致IIIA期患者(73例,40%)比I-II期患者(81例,32%)更常检测到复发。远处复发在IIIA期患者中比I-II期患者更常见(153例,85%,对190例,74%;p=0.01)。在IIIA期患者中,复发风险在术后的头2年最高,但到第4年仍然很高。
IIIA期患者通过监测CT检测到的复发较少,症状表现率较高,复发风险明显更高,远处复发倾向更高。监测策略可能需要考虑分期特异性差异。